Brokerages Anticipate Acorda Therapeutics Inc (NASDAQ:ACOR) to Post -$0.91 EPS

Equities analysts expect Acorda Therapeutics Inc (NASDAQ:ACOR) to report ($0.91) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Acorda Therapeutics’ earnings. The highest EPS estimate is ($0.88) and the lowest is ($0.94). Acorda Therapeutics reported earnings of $0.10 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 1,010%. The firm is expected to issue its next earnings results on Wednesday, October 30th.

On average, analysts expect that Acorda Therapeutics will report full-year earnings of ($2.97) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($3.11) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Acorda Therapeutics.

Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.53. Acorda Therapeutics had a negative net margin of 25.94% and a negative return on equity of 6.18%. The firm had revenue of $50.05 million for the quarter, compared to analyst estimates of $28.83 million. During the same period last year, the firm earned $1.40 earnings per share. The business’s quarterly revenue was down 67.4% compared to the same quarter last year.

A number of analysts recently issued reports on ACOR shares. JPMorgan Chase & Co. set a $7.00 price objective on shares of Acorda Therapeutics and gave the stock a “hold” rating in a report on Friday, August 2nd. Stifel Nicolaus reduced their price objective on shares of Acorda Therapeutics from $12.00 to $7.00 and set a “hold” rating for the company in a research note on Friday, August 2nd. Wedbush reduced their price objective on shares of Acorda Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Friday, August 2nd. HC Wainwright lowered shares of Acorda Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the company from $31.00 to $6.00 in a research report on Wednesday, August 14th. Finally, ValuEngine upgraded shares of Acorda Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 2nd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $12.73.

Shares of ACOR traded down $0.18 during trading hours on Tuesday, reaching $3.39. 2,344,500 shares of the stock traded hands, compared to its average volume of 1,127,895. The company has a current ratio of 3.81, a quick ratio of 3.52 and a debt-to-equity ratio of 0.69. The stock has a fifty day simple moving average of $3.43 and a 200 day simple moving average of $8.66. Acorda Therapeutics has a 52 week low of $2.27 and a 52 week high of $21.63. The company has a market cap of $169.83 million, a price-to-earnings ratio of 1.86 and a beta of 1.26.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Perceptive Advisors LLC purchased a new position in Acorda Therapeutics during the 2nd quarter valued at $8,647,000. Renaissance Technologies LLC increased its position in Acorda Therapeutics by 13.6% during the 2nd quarter. Renaissance Technologies LLC now owns 4,558,000 shares of the biopharmaceutical company’s stock valued at $34,960,000 after purchasing an additional 546,700 shares during the period. Acadian Asset Management LLC increased its position in Acorda Therapeutics by 57.9% during the 1st quarter. Acadian Asset Management LLC now owns 923,041 shares of the biopharmaceutical company’s stock valued at $12,268,000 after purchasing an additional 338,294 shares during the period. AXA increased its position in Acorda Therapeutics by 898.8% during the 2nd quarter. AXA now owns 240,700 shares of the biopharmaceutical company’s stock valued at $1,846,000 after purchasing an additional 216,600 shares during the period. Finally, Diamond Hill Capital Management Inc. increased its position in Acorda Therapeutics by 77.9% during the 2nd quarter. Diamond Hill Capital Management Inc. now owns 489,329 shares of the biopharmaceutical company’s stock valued at $3,753,000 after purchasing an additional 214,227 shares during the period.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

Read More: How to calculate the intrinsic value of a stock

Get a free copy of the Zacks research report on Acorda Therapeutics (ACOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.